Compare GOOS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | CADL |
|---|---|---|
| Founded | 1957 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.6M | 1.0B |
| IPO Year | 2016 | 2021 |
| Metric | GOOS | CADL |
|---|---|---|
| Price | $7.57 | $11.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $12.60 | ★ $19.00 |
| AVG Volume (30 Days) | 771.5K | ★ 1.1M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.36 | $4.35 |
| 52 Week High | $14.69 | $14.00 |
| Indicator | GOOS | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 46.98 |
| Support Level | $7.36 | $9.40 |
| Resistance Level | $8.32 | $11.36 |
| Average True Range (ATR) | 0.25 | 0.71 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 17.39 | 45.23 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.